Neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) are characterized by neuronal impairment that leads to disease-specific changes in the neuronal proteins. The early diagnosis of these disorders is difficult, thus, the need for identifying, developing and using valid clinically applicable biomarkers that meet the criteria of precision, specificity and repeatability is very vital. The application of rapidly emerging technology such as mass spectrometry (MS) in proteomics has opened new avenues to accelerate biomarker discovery, both for diagnostic as well as for prognostic purposes. This review summarizes the most recent advances in the mass spectrometry-based neuroproteomics and analyses the current and future directions in the biomarker discovery for the neurodegenerative diseases.
Introduction
The brain is the most fascinating and highly complex organ of the nervous system with the ability to control most of the body activities, and is responsible for perception, storage and process of memory, controlling psychological processes and behavioral aspects. The high diversity and heterogeneity of the brain pose a tremendous challenge for proteomic analysis.
Proteomics is a relatively recent field of research currently undergoing rapid development and growth. It covers the large-scale study of protein functions, interactions, dynamics and structures, complementing the genomic and transcriptomic studies. Recently, there has been a growing interest in applying proteomics to the clinical diagnosis of the disease. Clinical proteomics is increasingly used for the discovery and verifications of new diagnostic and prognostic biomarkers, novel drug targets, as well as for unraveling novel biological mechanisms [1] .
One of the important sub discipline of proteomics is "neuroproteomics" (established in 2003) [2] . The challenge of clinical neuroproteomics is to understand the protein-driven molecular mechanisms and functions of the central nervous system (CNS) and CNS disorders through the study of protein expression and the discovery of novel protein biomarkers in order to facilitate diagnosis, treatment monitoring and prognosis. Therefore clinical neuroproteomics is a very useful tool for meeting the needs of neurological disorders.
In general, the field of proteomics can be divided into two extensive areas based on the detection methods used: (1) approaches using mass spectrometry (MS) for the identification and quantitation of proteins and (2) approaches using antibody-based methods. MS-based proteomics has emerged as a powerful approach with the potential to accelerate biomarker discovery [3] . The possibility to analyze complex samples globally and to create comprehensive lists of possible candidate biomarkers makes mass spectrometers an indispensable tool for the discovery phase of biomarker research. Specificity, sensitivity, accuracy, acquisition speed and automation are all advantages offered by MS quantification.
As life expectancy is increasing, the number of elderly people at risk of developing dementia is growing rapidly. Dementia is one of the main causes of disability in later life. Age-related neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (here abbreviation MSc to distinguish from mass spectrometry MS), amyotrophic lateral sclerosis (ALS) are growing public health problems. Recently, it has been A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 4 estimated that more than 36 million have dementia today, with 4.6 million new cases of dementia every year. Numbers of people affected will double every 20 years to more than 66 million in 2030 and 115 million by 2050 [4, 5] . A failure to find a curative treatment, or even more challenging, to gain insight into the elusive context of understanding the disease's pathogenic mechanisms cause very large future costs to the national health care system. The main issue with these disorders is the difficulty in correctly clinical diagnosing the patient at an early phase of the disease. The clinical diagnosis of neurodegenerative disorders requires a medical history and a series of examinations including blood and cerebrospinal fluid (CSF)
tests, psychological assessments, imaging technologies, and different radiological investigations [6] . Therefore, the identification and validation of novel biomarkers for diagnosing of different form of dementia are increasingly important.
This review will discuss some important aspects of high-mass resolution MS-based clinical neuroproteomics, with a focus on recently published works in the field of protein biomarker discovery in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis, with the aim to provide a prospective view on current and future research aspects in this field. In our laboratory we have been studying the neuroproteome since early 2000 developing and applying novel sample preparation and proteomic approaches in neurodegenerative diseases [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . There are many other tools available for proteomic research including protein microarrays [18] , proximity ligation assay [19] , Luminex-based multiplex assay [20, 21] , Bio-Plex assay [22] , etc.
However description of them is beyond the frames of the current review. For more detailed information we refer the reader to specific reviews of each of these methodologies.
Biological samples -clinical specimen
In the search for protein biomarkers there are a few options of sample sources. Different tissues (brain biopsy, spinal cord, muscles, ets) or body fluids (blood, plasma, CSF, saliva, tears, urine) can be examined for protein biomarkers discovery. Choosing the appropriate biological sample is one of the most important steps in the discovery of biomarker candidates that might be suitable for clinical research and clinical use. 
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CNS tissue samples

Cerebrospinal fluid
For practical purposes, analysis of protein expression in body fluids is likely to provide important information about how the CSN is functioning both in normal healthy conditions and in neurological disorders. Body fluids can be easily obtained by non-invasive or minimally invasive techniques.
Human CSF is a valuable and promising body fluid for differential proteome analyses that provides molecular insights into the pathogeneses of CNS diseases and potentially provide biomarkers that can help in diagnoses and monitoring of disease progressions. CSF circulates within the ventricles of the brain and surrounds the whole spinal cord. It is created by passive filtration of blood through the epithelial cells and by diffusion of interstitial fluid from the brain renewing about four times every 24 hours [23] . The most common way to obtain CSF is via lumbar puncture. Routinely, 12 mL CSF is collected for analysis from adults [24] .
Since CSF is in a close proximity to the diseased brain tissue and in a close anatomical contact with the brain interstitial fluid, where biochemical changes related to CNS disease are reflected, it is an exceptional source of potential protein biomarkers for neurodegenerative disorders [25] . Therefore, the CSF analysis remains an important and practical tool to get closest to the pathology of CNS disorders. However, the major disadvantage of using CSF as the sample sources for clinical applications is the invasive nature of CSF sampling.
Additionally, the collection of CSF from healthy controls is still an ethical concern.
Furthermore, depletion of highly abundant proteins, such as albumin, IgG, transferrin, ets, is often desired prior to the proteome analysis of CSF [26] [27] [28] . Though the CSF collection is quite invasive and tricky, CSF is still the best biological sample source to perform biochemical and clinical analyses to detect pathophysiological abnormality of the CNS [29] (besides brain or spinal cord tissue).
Blood and serum/plasma
Human blood is the most frequently used body fluids for measuring levels of proteins and other biomolecules in clinical research, since they can be reasonably easy to sample and technically easy to process. The blood proteome is one of the most complex components of the human proteome, which contains a large diversity of proteins [30, 31] . Blood can be separated into two compartments, namely, plasma (cell-free content of the blood) and serum (plasma without the clotting factors, fibrinogens and includes all proteins not used for blood coagulation). Plasma and serum contain extremely informative proteomes that may present unique information from different tissues and organs in the body and may be an excellent sample for the discovery of potential clinical biomarkers and for their clinical quantification.
However, despite the simplicity of sampling, biomarker discovery from these samples has been lacking. The tremendous analytical challenge in the development of diagnostic assays for the very low concentration of biomarker proteins is the broad dynamic range of its protein constituents and complexity. The estimated dynamic range of protein concentrations in human plasma may be up to 15 orders of magnitude [30, 31] .
Additionally, the use of blood is still limited for biomarker discovery for neurological disorders. Proteomic research using blood as a source of protein biomarkers still did not answer the question whether there is a linear relationship between changes of proteins in diseased CNS tissue and in blood.
Saliva, tears, urine
Saliva is a multi constituent biological fluid that reflects the general body health and disease.
Being extremely readily accessible and containing about 30 % of blood proteins, saliva
represents an attractive diagnostic fluid for the early detection of various diseases including oral cancer, renal, and autoimmune diseases [32, 33] .
Tears are a complex fluid composed of many proteins, lipids, carbohydrates, electrolytes and other small organic molecules. The chemical composition of tears is significantly less complex as compared to plasma, CSF and urine. Additionally, the tear sample collection is non-invasive and pain free which makes tear fluid a good source for biomarker discovery studies of diseases such as, dry eye, visual disease, inflammatory disease, cancer, ets [34] .
However, despite of simple sampling of tears, the tear proteome profiling is quite challenging due to the very small volume of tear fluid (less than 5 μL) that can be collected under normal conditions [35] . Furthermore, different exogenous factors such as inflammatory or metabolic influences can easily effect the composition of saliva and tears leading to poor reproducible results in CNS diseases. The applicability of saliva in biomarker discovery for neurological disorders is extremely limited, to the best of our knowledge, only one study revealed novel alterations in saliva metabolomic profiles between various neurodegenerative disorders [36] .
Urine is one of the most useful human body fluids for clinical proteomics. It is generated as a result of filtration of plasma by glomeruli in the kidneys, retaining the majority of the proteins [37] . Urine is an easily accessible in a big amount sample source that has the potential to provide various disease specific biomarkers related to urogenital and some of nonnephrological diseases. Changes in urine composition are becoming also promising in biomarker discovery for neurological disorders. Metabolic [38] and lipidomic [39] signatures of AD and PD urine samples are reported in a few studies. However, to the best of our knowledge, only in one paper AD urinary proteome was characterized using ELISA approach revealing up-regulation of novel neural thread protein, a membrane-associated phosphoprotein, in the urine of patients with AD [40] . 
Technologies for mass spectrometry-based neuroproteomic analysis
Sample preparation
With the advances in the instrumentation, mass spectrometry has emerged into a powerful tool for the screening and discovery of potential biomarker candidates in addition to the traditional protein identification and characterization applications. The proteins/peptides required to be analyzed by MS should be free of contaminants to reduce their interference during electrospray ionization (ESI) and to prevent their dominant appearance in the chromatogram. Therefore, sample preparation plays a key role to produce a MS-compatible end product for the analysis. A C C E P T E D M A N U S C R I P T There is no universal detergent that can serve all the needs of proteomic research, and the choice of detergent selection is determined experimentally to suit the type of work to be carried out. However, the usage of detergents compromises with the MS analysis step to some extent due to-their interference in ionization step causing the shifts in charge-state distribution in ESI-MS [42] . Hence their removal prior to MS-analysis is essential, which can be achieved by different techniques such as dialysis, hydrophobic absorption, ultrafiltration, precipitation, gel filtration or solid phase extraction ( Table 1) . Selection of the purification method should be based on the characteristics of tissue to be studied as well as the desired end product. For example, in case of neuroproteomic studies on brain tissue, the removal of lipids (delipidation) is the main priority due to presence of 60% fat content in the brain [43] .
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Delipidation can be done by using various organic solvents to precipitate the proteins and to remove the lipids [15] .
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Apart from the purification techniques, cleavable detergents such as 3-[3-(1,1-
Corp) can be employed. Such detergents can be cleaved under acidic condition making them inactive and removable prior to the MS-analysis. Additionally, perfluorinated detergents [45] that do not interfere with ESI-MS can be used in proteomic analysis. Also organic solvents and organic acids can be used for the extraction of proteins. Organic solvents are compatible with trypsin digestion and can be removed easily by evaporation prior to LC-MS/MS analysis.
Chaotropes disrupt the ordered water structure, thus promoting the solubility of hydrophobic
MPs. Chaotropes alone cannot solubilize the lipids, for this reason a mixture of detergentchaotrope is often employed to increase the solubility of MPs and to solubilize the lipids [46] 
Protein/peptide separation
Separation of proteins/peptides is the pre-requisite prior to MS analysis of CNS sample (neuroproteomics) or any biological samples to reduce the complexity. Two-dimensional gel electrophoresis (2-DE) is a classical technique used in the separation of complex protein mixtures, to detect the qualitative and quantitative differences in the protein composition between two or more biological sample sets [47, 48] . In 2-DE proteins are separated in twodimensions by combining isoelectric focusing (IEF) and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). In the first dimension of IEF, separation is based on net charge at different pH. In the second dimension the separation is based on the molecular weight. Although 2DE served as a major workhorse in proteomic workflow, it has inherent limitations such as difficulty in reproducibility, poor resolving of low abundant, highly acidic/basic and hydrophobic proteins [48] . With the development in the MS instrumentation in 1990's, a huge leap in the proteomics and biomarker research was attained by replacing the time consuming chemical degradation methods with sensitive and reproducible MS technology.
The next step in sample preparation contains enzymatic cleavage of proteins into peptides.
Two types of proteomic approaches, in-gel digestion [49] and in-solution digestion [50, 51] , have been employed in many laboratories on a routine basis. In-gel digestion consists of
separation of proteins by SDS-PAGE) or 2-DE followed by picking the individual bands/spots and cleaving proteins into peptides using enzymatic digestion. In comparison, in-solution digestion approach involves enzymatic digestion of proteins into peptides in an aqueous solution. Both approaches can be performed by various proteases such as trypsin, chymotrypsin or lys-C, which cleave amino acid-specific peptide bonds. After protein digestion, peptides can be separated by one-or two-dimensional liquid chromatography (LC)
prior to ionization and mass spectrometry analysis.
Mass spectrometry identification
Mass spectrometry has become a versatile and indispensable tool for the analysis of proteins, to define protein-protein interactions and to identify the post-translational modifications (PTMs). The introduction of two soft ionization techniques ESI [52] and matrix-assisted laser desorption/ionization (MALDI) [53] has revolutionized the usage of MS for proteomics research.
ESI, introduced by Fenn and co-workers in 1980's [52] has emerged into a powerful technique in high-throughput proteomics workflow. In the ESI process, the protein/peptide solution is sprayed across a high potential difference to generate a mist of droplets carrying excess charge at the surface. The solvent is evaporated by passing through a heated capillary or by counter-flow of heated drying gas resulting in the closer movement of the droplets.
Droplets explode due to the Coulombic repulsive forces, resulting in smaller droplets and the process goes on until solvent-free ions are formed. In addition to ESI, the introduction of microspray and nanospray has greatly benefited the proteomics and biomarker research. The principle of both microspray and nanospray is similar to ESI but differs in needle diameter and the flow rates. With the reduced flow rates to nl/min, nanospray provides the advantage of improved sensitivity and less sample consumption which is important for biological samples [54] . Finally, ionized peptides are transferred into mass spectrometer, where the mass-to-charge ratio of peptides is detected. State-of-the-art mass spectrometers involve multiple steps of mass detection combined with high-energy fragmentation of peptides to achieve high mass accuracy (Tandem-MS). Identification of proteins occurs in the last step by correlating identified masses with known peptide masses based on data base search algorithms.
In MALDI process, the sample is co-crystallized with a suitable organic, UV-absorbing matrix (e.g., a-cyano-4-hydroxy cinnamic acid, sinapinic acid or 2,5-dihydroxybenzoic acid, ets) on a conductive surface. When irradiated with the laser, energy is transferred to the matrix and ionizes the analyte into the gas phase. Another recent approach MALDI-imaging mass spectrometry (IMS) is becoming a valuable tool in neuroproteomics to identify the distribution of neuropeptides and proteins directly in thin brain tissue sections [55] [56] [57] .
MALDI-IMS has advantage of creating three-dimensional images of brain to determine the evolution of sub-proteome [55, 58] .
Quantitative neuroproteomics
Quantitative neuroproteomics is frequently applied to measure the relative or absolute protein abundance between two or more conditions, e.g. normal versus disease state, to explore changes in the proteome and post-translational modifications based on neurological disorder or to discover novel protein biomarkers.
Over the last two decades, quantitative MS-based methods evolved tremendously based on technological improvements of mass spectrometry instrumentation and the development of methods for protein or peptide quantification including label and label-free techniques.
Several quantitative MS-methods were successfully applied to neuroproteomics studies like classical techniques using two-dimensional gel electrophoresis and differential twodimensional gel electrophoresis (2D-DIGE) as well as newer quantitative methods as isotopic chemical labeling (e.g. iTRAQ, dimethyl labeling (DML)), multiple reaction monitoring (MRM) and label-free quantification (Fig. 2) . [59] .
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Quantitative gel electrophoresis methods
2-DE and 2D-DIGE are classical and robust methods to compare protein expression levels between normal and disease states [60, 49, 61, 62] . As described before, protein spots are detected and can be compared between different 2D-gels by 2D-imaging analysis software.
The alignment of different gels should be carefully considered to ensure accuracy of quantification. To overcome the problem of gel-to-gel differences and therefore incorrect protein quantification, in 2D-DIGE approaches proteins are labeled by fluorescent cyanine dyes which allow the combined analysis of several samples on a single 2D-gel [62] . 
Chemical labeling methods
Coupled to significant improvements of mass spectrometry instrumentation, quantitative MS- [63] . Initially, proteins are enzymatically digested to peptides and then labeled with isobaric tags at the free amino-termini and epsilon-amino groups of lysine residues. The isobaric tags contain a reactive group for peptide binding, a balancer group, a cleavage site proteome studies were performed in our group using DML to analyze patients with AD [9] and ALS [65] .
Label-free quantification
In comparison to labeling techniques for quantitative MS-based proteomics, non-label methods have the benefit to utilize protein quantification without any kind stable isotope labeling. Therefore, label-free quantification is not laborious and can be applied to all biological samples. Two label-free techniques are frequently used: quantification based on peptide-ion intensity, which compare ion abundances of a peptide between LC-MS/MS runs, and spectral counting based on the numbers of MS/MS spectra per peptide [66, 67] . Both methods rely on the correlation that the ion abundance as well as the number of fragmentation spectra are linearly proportional to protein abundance in a single LC-MS/MS run.
Label-free quantification is suitable for proteomic studies using sub-cellular fractionation or chromatographic protein/peptide separation but it requires high resolution MS instrumentation and reproducibility across multiple samples to ensure high accuracy of quantification. For neuroproteomics studies, label-free quantification has been recently used to analyze changed protein expression e.g. in brain tissue of AD patients [68] and spinal cord tissue of ALS patients [69] .
Furthermore, newly developed methods for label-free quantification as SWATH [70] and MS E [71, 72] could gain in importance for neuroproteomics analysis due to high technical reproducibility and accuracy. Both techniques rely on data-independent acquisition of ion spectra. In SWATH experiments, all fragment ions are detected by cycling through specified precursor isolation windows, whereas all precursor and fragment ions are monitored at different collision energy levels in MS E mode. Due to high throughput protein identification and quantification as well as targeted data analysis strategy both methods might be established for clinical applications in the future.
Multiple-reaction monitoring
Multiple-reaction monitoring or selected reaction monitoring (SRM) is a MS-based, targeted protein measurement to detect relative and absolute peptide levels [73] . MRM is most widely performed on triple quadrupole mass spectrometer (QQQ), using the first quadrupole (Q1) for the selection of parent ions, the second quadrupole (Q2) for fragmentation and the third quadrupole (Q3) to scan and filter fragment ions.
In contrast to global protein profiling methods as described before, MRM allows the measurement of specific target peptides with high selectivity as well as with high sensitivity to detect low abundant proteins in complex samples. In addition, absolute protein quantification (AQUA) can also be performed by MRM using stable isotope containing tryptic or synthetic peptides.
In recent neuroproteomics studies, MRM was used to analyze the expression levels of targeted proteins in AD and MSc patients. Furthermore, MRM is a promising technique to complement Enzyme-linked Immunosorbent Assay (ELISA) assays as a diagnostic tool in clinical practice.
MS-based proteomics discoveries in neurodegenerative diseases
The Typically, the clinical diagnosis of such diseases cannot be made until the disease has progressed to the point that dementia or motoric dysfunctions arise. Although significant improvement in clinical diagnosis and care for patients with these diseases has been made, still there is currently no curative treatment for any of these disorders. Thus, the need for identification, development and validation of biomarkers for diagnosing different forms of dementia that meet the criteria of precision, specificity and repeatability is increasingly important. Additionally, it is extremely important to find reliable biomarkers that can distinguish neurodegenerative disorders to begin an early treatment.
In the following section, we will focus on biomarker discovery for the four most common CNS disorders: AD, PD, ALS and MSc using MS-based proteomic methods in order to summarize the recent advances in this rapidly developing field. Therefore, we will cover only a small part of proteomic research done in the field of biomarker discovery.
The overview of recently published neuroproteomic studies differentiating between AD, PD,
ALS, MSc and control samples, including the source of CNS samples, applied MS-based
techniques and the biomarker candidates discovered are listed in Table 2 .
Alzheimer's disease
AD is the most common form of neurodegenerative disease, accounting for 50-60 % of all diagnosed cases [74] . Although the exact etiology of AD remains to be defined, histopathologically AD is characterized by deposition of the aggregated β-amyloid (Aβ) peptide in the form of extracellular senile plaques and hyperphosphorylated tau protein in the form of intracellular neurofibrillary tangles causing massive neuronal and synaptic degeneration. Several neuropathological processes have been proposed to connect with the onset and progression of Alzheimer's disease. Primarily, the "amyloid cascade hypothesis" posits that accumulation of Aβ, cleaved from the amyloid precursor protein (APP) by β-secretase and γ-secretase [75] . Impaired mitochondrial functions, oxidative stress and inflammatory processes have also been suggested to play a role in AD pathogenesis [76] .
Currently, combined analysis of 42 amino acid form of Aβ (Aβ42), total tau (tTau) and hyperphosphorylated tau (pTau) in CSF are employed AD diagnosis [77] . CSF of AD patients
shows decreased values of Aβ42 and increased values of tTau or pTau. showed that the increased level of neural cell adhesion molecule 1 in the CSF of AD patients compared with normal controls is higher than that of PD patients, indicating that NCAM1 is a possible marker for distinguishing AD from PD. In another 2-DE study [81] , increased levels of clusterin and apolipoprotein J proteins were found in plasma of the AD patient samples compared to controls. Song et al. [82] detected a panel of 18 signal proteins as markers of AD and mild cognitive impairment using 2-DE and LC MS/MS approach.
Over the past years, the alternative gel-free MS-based proteomics approaches have been widely used for identification and quantification of possible CNS protein biomarkers that fall outside the range of 2-DE. Gel-free shotgun approach can be combined with quantitative proteomic technique, e.g. stable isotope labeling or label free method, and can be easily used for large-scale proteomic experiments. In our recent study [9] , by employing a stable isotope DML MS approach we identified 827 brain proteins, 69 of which were significantly changed in AD compared non-neurological control brains. A quantitative proteomic strategy based on the cloud-point extraction method for the separation and enrichment of hydrophobic MPs in combination with DML MS analysis was also employed by our group [17] to quantitatively identify protein expression changes in AD temporal neocortex samples. 62 proteins were found to be differentially regulated including three novel hydrophobic transmembrane proteins: down-regulated sarcoplasmic/endoplasmic reticulum calcium ATPase2 and upregulated orphan sodium-and chloride-dependent neurotransmitter transporter NTT4 and C9orf5.
Label free quantitative proteomics was used to investigate the protein expression in the brain cortex [68, 83] and substantia nigra [84] of AD patients, leading to the identification of 197, 13 and 19 differentially expressed proteins, respectively.
The Aβ isoform pattern in CSF and brain tissue samples has been the subject of extensive target proteomic studies aimed to distinguish AD patients from non-demented subjects.
Pannee et al. [85] have applied MRM-MS technique to quantify aβ42, aβ40 and aβ38 in human CSF. Apolipoprotein E has also been measured in serum using this approach, showing a significant decrease of its level in serum of AD patients [86] . Choi et al. [87] reported on a nanoLC-MRM/MS analytical assays for the measurements of the Aβ1-40, Aβ1-42, retinolbinding protein and cystatin C in human CSF and validated MS findings using ELISA.
Recently, immunoaffinity enrichment technique, e.g. immunoprecipitation, followed by high resolution MS, was used to analyze the levels of two species APPα and APPβ in CSF from AD and non-demented controls [88] . Portelius et al. [89] have demonstrated the ability to apply immunoprecipitation in combination with MALDI-TOF MS or LC-MS/MS to determine the Aβ isoform pattern in the cerebellum, cortex and hippocampus of AD subjects.
Combination of immunoprecipitation and LC-MS/MS approach was used by Thorsell et al.
[ 90] for the determination of neurogranin in the CSF samples. The results reveal a significant increase in the neurogranin levels in the CSF from AD patients and a trend towards increasing levels in the MCI group.
Parkinson's disease
Parkinson's disease is the second most common progressive degenerative CNS after AD. It characterized by motor function impairment caused by loss of the dopamine (DA)-containing neurons in the brainstem and the presence of intracellular protein inclusions in the substantia nigra, known as Lewy bodies. It is suggested that the abnormal accumulation of proteins, particularly heavily ubiquitinated alpha-synuclein (α-syn), may play role in the pathogenesis of PD [91] . Diagnosis of typical cases of PD is mainly based on symptoms as well as on clinical tests e.g. computed tomography and magnetic resonance imaging of brain scans. Targeted proteomics has also been using in the study of PD. Using a immunoprecipitation method combined with LC-MS/MS approach Öhrfelt et al. [99] were able to detect and identify known and novel isoforms of alpha-synuclein in PD brain tissue homogenates, including N-terminally acetylated full-length α-syn and two N-terminally acetylated truncated forms of α-syn. Lehnert et al. [100] detected 16 proteins altered in CSF of PD patients using iTRAQ labeling method. Validation of these candidates was then carried out by MRM method, confirming however that only tyrosine-kinase non-receptor-type 13 and netrin G1
were significantly changed in PD and control subjects.
Hong et al. [101] have recently published the biggest proteomic study on CSF levels of alphasynuclein and observed reduced levels of α-syn in more than 100 PD patients compared to both 50 AD patients and 132 controls after controlling for blood contamination. Additionally, they found DJ-1 as another potential protein candidate which level was significantly decreased in PD cases versus controls or AD patients.
Amyotrophic lateral sclerosis
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Amyotrophic lateral sclerosis is an incurable and the most common type of adult motor neuron disease that leads to progressive paralysis and death within a few years of onset [102] . samples. These metals are essential for many metabolic processes and are related to neurodegenerative disease [103] . Elevated levels of alpha-1-antitrypsin have also been presented in CSF samples in two different proteomic studies using MALDI-TOF MS approach [104, 105] . Furthermore, Brettschneider et al. [105] have found increased levels of heat shock protein1, fetuin-A precursor, transferrin, nebulin-related anchoring protein and transthyretin in ALS CSF samples. Interestingly, that SELDI-TOF-MS analysis performed by Ryberg et al. [106] has shown the reduced levels of native transthyretin and increased levels of cysteinyl-glycine-transthyretin, a modified form generated by oxidative damage. 
Multiple sclerosis
Multiple sclerosis is the most common cause of chronic disabling disorder of CNS and is generally regarded as an autoimmune disease to myelin components that occurs in young adults. MSc is characterized clinically by a variable remitting relapsing and relapsing course and pathologically by the chronic inflammation in the CNS causing axonal damage, progressive accumulation of focal plaques of demyelination in the white matter and neurologic disability [107] . MSc can be divided into two main types: a relapsing type and a progressive type. Both MSc types starts with an episode of so-called clinically isolated syndrome (CIS) [108] . The etiology of the disease is still unknown and currently there is no available diagnostic test to predict disease course and prognosis in individual patients.
Currently, magnetic resonance imaging and evidence of dissemination of the lesions in space and time are used for the diagnosis of MSc [109] .
In recent years a number of papers appeared describing proteomic analysis of CSF or brain tissue of MSc patients. 2D-E and 2D-DIGE has been widely used in many of the studies in biomarker discovery for MSc. In order to elucidate proteome signatures, Amin et al. [110] used 2D-DIGE MS/MS to compare the protein expression profile in serum of different A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T 
